Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of GDC-0980 in Combination With Either Paclitaxel and Carboplatin (With or Without Bevacizumab) or Pemetrexed and Cisplatin in Patients With Solid Tumors

NCT01301716 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT01301716
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01301716 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of GDC-0980 in Combination With Either Paclitaxel and Carboplatin (With or Without Bevacizumab) or Pemetrexed and Cisplatin in Patients With Solid Tumors
Lead sponsor
Genentech, Inc.
Phase
Phase 1
Overall status
Completed
Start date
September 30, 2011
Completion date
August 31, 2014
Enrollment
75 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

solid cancers